Skip to content

Gross Profit at other companies

Eli Lilly logo
Eli LillyLLY
$16.22B+54.4%
Alkermes logo
AlkermesALKS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
TG Therapeutics logo
TG TherapeuticsTGTX
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$6.64B+77.3%
Enterprise value$6.69B+78.4%
P/S30.6×+3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Calculated from Rhythm Pharmaceuticals, Inc.’s reported figures.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s gross profit?
Rhythm Pharmaceuticals, Inc. (RYTM) reported gross profit of $52.96M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s gross profit changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s gross profit increased by 82.3% year-over-year, from $29.06M to $52.96M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s gross profit?
Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s gross profit has grown at a 185.7% compound annual growth rate (CAGR), from $2.56M to $170.27M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.